摘要
目的:应用网络药理学方法探讨热毒宁(RDN)治疗新型冠状病毒肺炎(COVID-19)的可能机制。方法:利用中药系统药理学数据库和分析平台检索RDN的潜在入血活性成分和靶点。通过GeneCards与OMIM数据库检索COVID-19相关靶点。利用STRING构建RDN靶点与COVID-19靶点的蛋白质互作网络。利用Bioconductor对作用靶点进行GO功能和KEGG通路富集分析。结果:根据口服生物利用度类药性筛选出50种有效成分及170个作用靶点,从GeneCards与OMIM数据库中筛选靶点253个。成分靶点与疾病靶点取交集获得43个基因。这些基因主要参与细胞内脂多糖反应、氧化应激反应、对机械刺激的反应等生物学过程。分子功能主要与细胞因子受体结合、细胞因子活性、受体配体活性等有关。它们在细胞质、细胞膜等部位富集。其机制与IL17信号通路、TNF信号通路、甲型流感等信号通路有关。结论:RDN中的活性化合物可能通过抗病毒和抗炎等作用对COVID-19导致的感染、炎症以及肺损伤疾病产生治疗作用,研究结果可为中医药治疗COVID-19提供一定的理论依据。
Objective:To investigate the possible mechanism of Reduning(RDN)in the treatment of Corona Virus Disease 2019(COVID-19)by network pharmacology.Methods:The potential blood active components and targets of RDN were searched by using TCM systematic pharmacology database and analysis platform.COVID-19 related targets were searched through GeneCards and OMIM databases.Protein-protein interaction network of RDN component-targets and COVID-19 disease-targets was constructed by STRING.Bioconductor was used to conduct enrichment analysis of GO function and KEGG pathway.Results:50 active ingredients and 170 targets were screened according to oral bioavailability and drug-likeress,253 targets were screened through GeneCards and OMIM databases,43 genes were obtained from the intersection of component-target and disease-target.These genes were mainly involved in the cellular lipopolysaccharide reaction,oxidative stress response,response to mechanical stimulation and other biological processes.Molecular functions were mainly related to cytokine receptor binding,cytokine activity,receptor ligand activity and so on.They were enriched in the cytoplasm,cell membrane and other regions.The mechanism was related to IL17 signaling pathway,TNF signaling pathway,Influenza A and so on.Conclusion:The active compounds in RDN may have therapeutic effects on infection,inflammation and lung injury caused by COVID-19 through antiviral and anti-inflammatory effects.These results can provide certain theoretical and scientific basis for the treatment of COVID-19 by traditional Chinese medicine.
作者
蔡孟成
金永生
CAI Meng-cheng;JIN Yong-sheng(Naval Medical University,Shanghai 200433,China)
出处
《中药材》
CAS
北大核心
2021年第2期504-510,共7页
Journal of Chinese Medicinal Materials
基金
国家自然科学基金项目(81573585)